Eliava Institute of Phage Therapy
Eliava Phage Therapy Center (Eliava Institute)

The specialist doctors at the Eliava Institute
Giorgi Eliava and the creation of the Eliava Institute
The Eliava Phage Therapy Institute supplied and treated the entire Soviet Union with bacteriophages (phages) for decades, and still now supplies Ukraine, Poland, Russia, and of course, Georgia.
The Eliava Institute is the only center in the world that has such a bank of bacteriophages (6000) and such experience. Their doctors, scientists, and laboratories constantly practice phage therapy and are the world experts in it.
Dr. Dea NIZARADZE-Chief Medical Officer of the Phage Therapy Center)
Dr. Dea Nizaradze is one of the central figures at the Eliava Phage Therapy Center in Tbilisi. A physician specialized in internal medicine and an expert in infectious diseases, she has extensive clinical experience in managing chronic and multi-drug resistant (MDR) infections.
Recognized for her compassionate and rigorous approach, she plays a pivotal role in:
The development of personalized protocols tailored to each patient.
The supervision of bacteriophage treatments, from the diagnostic phase to post-treatment follow-up.
Welcoming international patients, for whom she often serves as the primary medical contact.
Her work bridges the historic scientific legacy of the Eliava Institute and contemporary medical standards, making her a valuable ally for patients seeking therapeutic alternatives to antibiotic resistance.
Official English-speaking partner of the Eliava Institute
When the Eliava Institute chooses your facilitator, you can move forward with complete confidence.
Travelling abroad for medical treatment is an act of trust. For this journey to feel safe and well supported, you need to know that the doctors treating you also trust the people accompanying you. After 11 years of collaboration, the Eliava Institute has officially recognised our service as its reference partner for English-speaking patients — a mutual trust from which you are the first to benefit.